Loading…
The acquisition includes established European patient access and U.S. development potential.
Splash Beverage Group, Inc. (NYSE: SBEV) announced the acquisition of exclusive global rights to CannEpil®, an epilepsy therapy. The acquisition includes established patient access in Europe, ongoing FDA engagement, and potential for U.S. development.
The therapy has shown promise in European markets and holds potential for further development and distribution in the United States.
With 15,389,840 shares outstanding and a free float of 2,264,392, the acquisition could influence the company's strategic direction in the healthcare sector.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.